NEW YORK, Oct. 10, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder andconsumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against TG Therapeutics, Inc. ("TG" or the "Company") (NASDAQ: TGTX) and other defendants, related to alleged violations of federal securities laws. If you purchased TG Therapeutics securities between June 4, 2018 and September 25, 2018, you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information
TG is a developmental biopharmaceutical company focused on treatments for B-cell malignancies and autoimmune diseases. The Company has been developing two therapies targeting hematologic malignancies: TG-1101 (ublituximab) and TGR-1202 (umbralisib).
During the class period, TG was engaged in a randomized controlled Phase 3 trial to evaluate TG-1101 in combination with TGR-1202 for patients with front-line and previously treated Chronic Lymphocytic Leukemia ("CLL"), known as the UNITY-CLL Trial.
The lawsuit alleges that defendants made false and misleading statements regarding TG's business and prospects and the UNITY-CLL Trial.
On September 25, 2018, pre-market, TG announced that it would not be releasing the data from the UNITY-CLL Trial and that it had failed to meet the trial's stated goal.
On this news, the price of TG stock fell from $9.25 per share to $5.15 per share a drop of over 44%.
What You Can Do
If you purchased TG Therapeutics securities between June 4, 2018 and September 25, 2018, inclusive, or if you have questions about this notice or your legal rights, please contact attorney Joe Pettigrew at (844) 818-6982, or at email@example.com. The lead plaintiff deadline is December 3, 2018.
About Scott+Scott Attorneys at Law LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.
Joe PettigrewScott+Scott Attorneys at Law LLP230 Park Ave, 17 Fl, NY, NY 10169-1820(844) firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/scottscott-attorneys-at-law-llp-alerts-investors-to-securities-class-action-against-tg-therapeutics-inc-tgtx-300728804.html
SOURCE Scott+Scott Attorneys at Law LLP
Subscribe to our Free Newsletters!
FDA approved elapegademase-lvlr injection for intramuscular use is used as an enzyme replacement ...
Armpit lumps and raised bumps in the armpits caused by infection, cysts and other types of ...
Bad eating habits will affect your health as well as your skin and make you look older than your ...View All